NCT02481154View on ClinicalTrials.gov

Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation

PHASE1CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

October 17, 2022

Study Completion Date

June 19, 2024

Conditions
Glioma
Interventions
DRUG

AG881

AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity

Trial Locations (9)

10065

Memorial Sloan Kettering Cancer Center, New York

27710

Duke University Medical Center, Durham

33136

University of Miami, Miami

37203

Sarah Cannon Research Institute, Nashville

75390

MD Anderson Cancer Center, Houston

77030

UT Southwestern Medical Center, Dallas

90024

UCLA Oncology Center, Los Angeles

94143

University of California San Francisco, San Francisco

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Institut de Recherches Internationales Servier

OTHER

NCT02481154 - Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation | Biotech Hunter | Biotech Hunter